{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:27:10Z","timestamp":1792067230043,"version":"4.4.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2014,10,30]],"date-time":"2014-10-30T00:00:00Z","timestamp":1414627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2014,10,30]],"date-time":"2014-10-30T00:00:00Z","timestamp":1414627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Malignant glioma is a severe type of brain tumor with a poor prognosis and few options for therapy. The main chemotherapy protocol for this type of tumor is based on temozolomide (TMZ), albeit with limited success. Cisplatin is widely used to treat several types of tumor and, in association with TMZ, is also used to treat recurrent glioma. However, several mechanisms of cellular resistance to cisplatin restrict therapy efficiency. In that sense, enhanced DNA repair, high glutathione levels and functional p53 have a critical role on cisplatin resistance. In this work, we explored several mechanisms of cisplatin resistance in human glioma. We showed that cellular survival was independent of the p53 status of those cells. In addition, in a host-cell reactivation assay using cisplatin-treated plasmid, we did not detect any difference in DNA repair capacity. We demonstrated that cisplatin-treated U138MG cells suffered fewer DNA double-strand breaks and DNA platination. Interestingly, the resistant cells carried higher levels of intracellular glutathione. Thus, preincubation with the glutathione inhibitor buthionine sulfoximine (BSO) induced massive cell death, whereas\n                    <jats:italic>N<\/jats:italic>\n                    -acetyl cysteine, a precursor of glutathione synthesis, improved the resistance to cisplatin treatment. In addition, BSO sensitized glioma cells to TMZ alone or in combination with cisplatin. Furthermore, using an\n                    <jats:italic>in vivo<\/jats:italic>\n                    model the combination of BSO, cisplatin and TMZ activated the caspase 3\u20137 apoptotic pathway. Remarkably, the combined treatment did not lead to severe side effects, while causing a huge impact on tumor progression. In fact, we noted a remarkable threefold increase in survival rate compared with other treatment regimens. Thus, the intracellular glutathione concentration is a potential molecular marker for cisplatin resistance in glioma, and the use of glutathione inhibitors, such as BSO, in association with cisplatin and TMZ seems a promising approach for the therapy of such devastating tumors.\n                  <\/jats:p>","DOI":"10.1038\/cddis.2014.465","type":"journal-article","created":{"date-parts":[[2014,10,30]],"date-time":"2014-10-30T10:14:46Z","timestamp":1414664086000},"page":"e1505-e1505","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":137,"title":["Glutathione depletion sensitizes cisplatin- and temozolomide-resistant glioma cells in vitro and in vivo"],"prefix":"10.1038","volume":"5","author":[{"given":"C R R","family":"Rocha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C C M","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D B","family":"Vieira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Quinet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L C","family":"de Andrade-Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Munford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J E","family":"Beliz\u00e1rio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C F M","family":"Menck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,10,30]]},"reference":[{"key":"BFcddis2014465_CR1","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1056\/NEJMra0708126","volume":"359","author":"PY Wen","year":"2008","unstructured":"Wen PY, Kesari S . Malignant gliomas in adults. N Engl J Med 2008; 359: 492\u2013507.","journal-title":"N Engl J Med"},{"key":"BFcddis2014465_CR2","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/1476-4598-10-128","volume":"10","author":"D Beier","year":"2011","unstructured":"Beier D, Schulz J, Beier C . Chemoresistance of glioblastoma cancer stem cells \u2013much more complex than expected. Mol Cancer 2011; 10: 128.","journal-title":"Mol Cancer"},{"key":"BFcddis2014465_CR3","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1586\/era.12.37","volume":"12","author":"T-CA Johannessen","year":"2012","unstructured":"Johannessen T-CA, Bjerkvig R . Molecular mechanisms of temozolomide resistance in glioblastoma multiforme. Expert Rev Anticancer Ther 2012; 12: 635\u2013642.","journal-title":"Expert Rev Anticancer Ther"},{"key":"BFcddis2014465_CR4","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/sj.onc.1209785","volume":"26","author":"WP Roos","year":"2007","unstructured":"Roos WP, Batista LFZ, Naumann SC, Wick W, Weller M, Menck CFM et al. Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. Oncogene 2007; 26: 186\u2013197.","journal-title":"Oncogene"},{"key":"BFcddis2014465_CR5","doi-asserted-by":"publisher","first-page":"11886","DOI":"10.1158\/0008-5472.CAN-07-2964","volume":"67","author":"LFZ Batista","year":"2007","unstructured":"Batista LFZ, Roos WP, Christmann M, Menck CFM, Kaina B . Differential sensitivity of malignant glioma cells to methylating and chloroethylating anticancer drugs: p53 determines the switch by regulating xpc, ddb2, and DNA double-strand breaks. Cancer Res 2007; 67: 11886\u201311895.","journal-title":"Cancer Res"},{"key":"BFcddis2014465_CR6","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/nrc2167","volume":"7","author":"L Kelland","year":"2007","unstructured":"Kelland L . The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007; 7: 573\u2013584.","journal-title":"Nat Rev Cancer"},{"key":"BFcddis2014465_CR7","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.ejca.2005.06.031","volume":"42","author":"MJ Van den Bent","year":"2006","unstructured":"Van den Bent MJ, Hegi ME, Stupp R . Recent developments in the use of chemotherapy in brain tumours. Eur J Cancer 2006; 42: 582\u2013588.","journal-title":"Eur J Cancer"},{"key":"BFcddis2014465_CR8","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1038\/onc.2011.384","volume":"31","author":"L Galluzzi","year":"2012","unstructured":"Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O et al. Molecular mechanisms of cisplatin resistance. Oncogene 2012; 31: 1869\u20131883.","journal-title":"Oncogene"},{"key":"BFcddis2014465_CR9","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1111\/j.1464-410X.2005.05472.x","volume":"95","author":"S-S Byun","year":"2005","unstructured":"Byun S-S, Kim SW, Choi H, Lee C, Lee E . Augmentation of cisplatin sensitivity in cisplatin-resistant human bladder cancer cells by modulating glutathione concentrations and glutathione-related enzyme activities. BJU Int 2005; 95: 1086\u20131090.","journal-title":"BJU Int"},{"key":"BFcddis2014465_CR10","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1002\/ijc.21919","volume":"119","author":"FJP Hoebers","year":"2006","unstructured":"Hoebers FJP, Pluim D, Verheij M, Balm AJM, Bartelink H, Schellens JHM et al. Prediction of treatment outcome by cisplatin\u2013DNA adduct formation in patients with stage III\/IV head and neck squamous cell carcinoma, treated by concurrent cisplatin-radiation (RADPLAT). Int J Cancer 2006; 119: 750\u2013756.","journal-title":"Int J Cancer"},{"key":"BFcddis2014465_CR11","first-page":"2253","volume":"3","author":"F Ali-Osman","year":"1997","unstructured":"Ali-Osman F, Brunner JM, Kutluk TM, Hess K . Prognostic significance of glutathione S-transferase pi expression and subcellular localization in human gliomas. Clin Cancer Res 1997; 3: 2253\u20132261.","journal-title":"Clin Cancer Res"},{"key":"BFcddis2014465_CR12","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/cyto.b.20450","volume":"76B","author":"PL Olive","year":"2009","unstructured":"Olive PL, Ban\u00e1th JP . Kinetics of H2AX phosphorylation after exposure to cisplatin. Cytom Part B 2009; 76B: 79\u201390.","journal-title":"Cytom Part B"},{"key":"BFcddis2014465_CR13","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1111\/j.1751-1097.2011.00995.x","volume":"87","author":"JE Cleaver","year":"2011","unstructured":"Cleaver JE . \u03b3H2Ax: biomarker of damage or functional participant in dna repair \u2018All that Glitters Is not Gold!\u2019. Photochem Photobiol 2011; 87: 1230\u20131239.","journal-title":"Photochem Photobiol"},{"key":"BFcddis2014465_CR14","doi-asserted-by":"crossref","unstructured":"Santos J, Meyer J, Mandavilli B, Houten B . Quantitative PCR-based measurement of nuclear and mitochondrial DNA damage and repair in mammalian cells. DNA Repair 2006: 183\u2013199.","DOI":"10.1385\/1-59259-973-7:183"},{"key":"BFcddis2014465_CR15","doi-asserted-by":"publisher","first-page":"e24665","DOI":"10.1371\/journal.pone.0024665","volume":"6","author":"CR Oliva","year":"2011","unstructured":"Oliva CR, Moellering DR, Gillespie GY, Griguer CE . Acquisition of chemoresistance in gliomas is associated with increased mitochondrial coupling and decreased ROS production. PLoS One 2011; 6: e24665.","journal-title":"PLoS One"},{"key":"BFcddis2014465_CR16","doi-asserted-by":"publisher","first-page":"9730","DOI":"10.1158\/0008-5472.CAN-10-1882","volume":"70","author":"CK Kim","year":"2010","unstructured":"Kim CK, Nguyen TLX, Joo KM, Nam D-H, Park J, Lee K-H et al. Negative regulation of p53 by the long isoform of ErbB3 binding protein Ebp1 in brain tumors. Cancer Res 2010; 70: 9730\u20139741.","journal-title":"Cancer Res"},{"key":"BFcddis2014465_CR17","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/sj.cgt.7700724","volume":"11","author":"K Datta","year":"2004","unstructured":"Datta K, Shah P, Srivastava T, Mathur SG, Chattopadhyay P, Sinha S . Sensitizing glioma cells to cisplatin by abrogating the p53 response with antisense oligonucleotides. Cancer Gene Ther 2004; 11: 525\u2013531.","journal-title":"Cancer Gene Ther"},{"key":"BFcddis2014465_CR18","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s11060-007-9436-x","volume":"86","author":"U Tallen","year":"2008","unstructured":"Tallen U, Truss M, Kunitz F, Wellmann S, Unryn B, Sinn B et al. Down-regulation of the inhibitor of growth 1 (ING1) tumor suppressor sensitizes p53-deficient glioblastoma cells to cisplatin-induced cell death. J Neurooncol 2008; 86: 23\u201330.","journal-title":"J Neurooncol"},{"key":"BFcddis2014465_CR19","first-page":"119","volume":"28","author":"CM Park","year":"2006","unstructured":"Park CM, Park MJ, Kwak HJ, Moon SI, Yoo DH, Lee HC et al. Induction of p53-mediated apoptosis and recovery of chemosensitivity through p53 transduction in human glioblastoma cells by cisplatin. Int J Oncol 2006; 28: 119\u2013125.","journal-title":"Int J Oncol"},{"key":"BFcddis2014465_CR20","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1158\/1078-0432.CCR-07-2238","volume":"14","author":"LP Martin","year":"2008","unstructured":"Martin LP, Hamilton TC, Schilder RJ . Platinum resistance: the role of DNA repair pathways. Clin Cancer Res 2008; 14: 1291\u20131295.","journal-title":"Clin Cancer Res"},{"key":"BFcddis2014465_CR21","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1172\/JCI115080","volume":"87","author":"RJ Parker","year":"1991","unstructured":"Parker RJ, Eastman A, Bostick-Bruton F, Reed E . Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin\u2013DNA lesions and reduced drug accumulation. J Clin Invest 1991; 87: 772\u2013777.","journal-title":"J Clin Invest"},{"key":"BFcddis2014465_CR22","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/S0006-2952(00)00441-X","volume":"60","author":"KV Ferry","year":"2000","unstructured":"Ferry KV, Hamilton TC, Johnson SW . Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ercc1\u2013xpf. Biochem Pharmacol 2000; 60: 1305\u20131313.","journal-title":"Biochem Pharmacol"},{"key":"BFcddis2014465_CR23","first-page":"1311","volume":"63","author":"M Selvakumaran","year":"2003","unstructured":"Selvakumaran M, Pisarcik DA, Bao R, Yeung AT, Hamilton TC . Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res 2003; 63: 1311\u20131316.","journal-title":"Cancer Res"},{"key":"BFcddis2014465_CR24","doi-asserted-by":"publisher","first-page":"430939","DOI":"10.1155\/2010\/430939","volume":"2010","author":"HHW Chen","year":"2010","unstructured":"Chen HHW, Kuo MT . Role of glutathione in the regulation of Cisplatin resistance in cancer chemotherapy. Met Based Drugs 2010; 2010: 430939.","journal-title":"Met Based Drugs"},{"key":"BFcddis2014465_CR25","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1002\/(SICI)1097-0215(20000320)89:2<160::AID-IJC10>3.0.CO;2-J","volume":"89","author":"PJ Van de Vaart","year":"2000","unstructured":"Van de Vaart PJ, Belderbos J, de Jong D, Sneeuw KC, Majoor D, Bartelink H et al. DNA-adduct levels as a predictor of outcome for NSCLC patients receiving daily cisplatin and radiotherapy. Int J Cancer 2000; 89: 160\u2013166.","journal-title":"Int J Cancer"},{"key":"BFcddis2014465_CR26","first-page":"312","volume":"63","author":"CM Rudin","year":"2003","unstructured":"Rudin CM, Yang Z, Schumaker LM, VanderWeele DJ, Newkirk K, Egorin MJ et al. Inhibition of glutathione synthesis reverses Bcl-2-mediated cisplatin resistance. Cancer Res 2003; 63: 312\u2013318.","journal-title":"Cancer Res"},{"key":"BFcddis2014465_CR27","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1200\/JCO.1996.14.1.249","volume":"14","author":"PJ O\u2019Dwyer","year":"1996","unstructured":"O\u2019Dwyer PJ, Hamilton TC, LaCreta FP, Gallo JM, Kilpatrick D, Halbherr T et al. Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer. J Clin Oncol 1996; 14: 249\u2013256.","journal-title":"J Clin Oncol"},{"key":"BFcddis2014465_CR28","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S0009-2797(98)00008-8","volume":"111","author":"P Calvert","year":"1998","unstructured":"Calvert P, Yao K-S, Hamilton TC, O\u2019Dwyer PJ . Clinical studies of reversal of drug resistance based on glutathione. Chem Biol Interact 1998; 111: 213\u2013224.","journal-title":"Chem Biol Interact"},{"key":"BFcddis2014465_CR29","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987\u2013996.","journal-title":"N Engl J Med"},{"key":"BFcddis2014465_CR30","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S1383-5742(00)00017-X","volume":"462","author":"AE Pegg","year":"2000","unstructured":"Pegg AE . Repair of O6-alkylguanine by alkyltransferases. Mutat Res 2000; 462: 83\u2013100.","journal-title":"Mutat Res"},{"key":"BFcddis2014465_CR31","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","volume":"10","author":"R Stupp","year":"2009","unstructured":"Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJB, Janzer RC et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10: 459\u2013466.","journal-title":"Lancet Oncol"},{"key":"BFcddis2014465_CR32","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/S0022-3565(24)39120-7","volume":"294","author":"S D\u2019Atri","year":"2000","unstructured":"D\u2019Atri S, Graziani G, Lacal PM, Nistic\u00f2 V, Gilberti S, Faraoni I et al. Attenuation of O6-methylguanine-DNA methyltransferase activity and mRNA levels by cisplatin and temozolomide in jurkat cells. J Pharmacol Exp Ther 2000; 294: 664\u2013671.","journal-title":"J Pharmacol Exp Ther"},{"key":"BFcddis2014465_CR33","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1200\/JCO.2004.11.019","volume":"22","author":"AA Brandes","year":"2004","unstructured":"Brandes AA, Basso U, Reni M, Vastola F, Tosoni A, Cavallo G et al. First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: A Phase II Study of the Gruppo Italiano Cooperativo di Neuro-Oncologia. J Clin Oncol 2004; 22: 1598\u20131604.","journal-title":"J Clin Oncol"},{"key":"BFcddis2014465_CR34","first-page":"4275","volume":"29","author":"F Zustovich","year":"2009","unstructured":"Zustovich F, Lombardi G, Della Puppa A, Rotilio A, Scienza R, Pastorelli D . A phase II study of cisplatin and temozolomide in heavily pre-treated patients with temozolomide-refractory high-grade malignant glioma. Anticancer Res 2009; 29: 4275\u20134279.","journal-title":"Anticancer Res"},{"key":"BFcddis2014465_CR35","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1023\/B:NEON.0000013479.64348.69","volume":"66","author":"A Silvani","year":"2004","unstructured":"Silvani A, Eoli M, Salmaggi A, Lamperti E, Maccagnano E, Broggi G et al. Phase II trial of cisplatin plus temozol omide, in recurrent and progressive malignant glioma patients. J Neurooncol 2004; 66: 203\u2013208.","journal-title":"J Neurooncol"},{"key":"BFcddis2014465_CR36","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.canlet.2012.12.005","volume":"331","author":"S Kohsaka","year":"2013","unstructured":"Kohsaka S, Takahashi K, Wang L, Tanino M, Kimura T, Nishihara H et al. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma. Cancer Lett 2013; 331: 68\u201375.","journal-title":"Cancer Lett"},{"key":"BFcddis2014465_CR37","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1016\/j.ejca.2010.12.008","volume":"47","author":"L Tentori","year":"2011","unstructured":"Tentori L, Dorio AS, Mazzon E, Muzi A, Sau A, Cuzzocrea S et al. The glutathione transferase inhibitor 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) increases temozolomide efficacy against malignant melanoma. Eur J Cancer 2011; 47: 1219\u20131230.","journal-title":"Eur J Cancer"},{"key":"BFcddis2014465_CR38","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1002\/humu.22259","volume":"34","author":"DT Soltys","year":"2013","unstructured":"Soltys DT, Rocha CRR, Lerner LK, de Souza TA, Munford V Cabral F et al. Novel XPG (ERCC5) mutations affect DNA repair and cell survival after ultraviolet but not oxidative stress. Hum Mutat 2013; 34: 481\u2013489.","journal-title":"Hum Mutat"}],"updated-by":[{"DOI":"10.1038\/cddis.2015.101","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2015,4,16]],"date-time":"2015-04-16T00:00:00Z","timestamp":1429142400000}}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/cddis2014465.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/cddis2014465","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/cddis2014465.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T18:25:27Z","timestamp":1746469527000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/cddis2014465"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,30]]},"references-count":38,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2014,10]]}},"alternative-id":["BFcddis2014465"],"URL":"https:\/\/doi.org\/10.1038\/cddis.2014.465","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,30]]},"assertion":[{"value":"9 June 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2014","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2014","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2014","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2015","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article has been corrected since Online Publication and a corrigendum has also been published","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}